$1.14 Billion is the total value of BVF INC/IL's 57 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 23.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARRY | Buy | ARRAY BIOPHARMA INC | $95,617,000 | +22.0% | 6,290,586 | +34.6% | 8.40% | +9.8% |
| CCXI | Sell | CHEMOCENTRYX INC | $85,620,000 | -7.6% | 6,773,760 | -3.7% | 7.52% | -16.8% |
| MRUS | MERUS N V | $77,280,000 | -13.3% | 3,914,913 | 0.0% | 6.79% | -21.9% | |
| CYTK | Sell | CYTOKINETICS INC | $51,090,000 | +10.9% | 5,186,839 | -6.6% | 4.49% | -0.2% |
| FPRX | Buy | FIVE PRIME THERAPEUTICS INC | $47,065,000 | +163.5% | 3,381,117 | +199.3% | 4.14% | +137.3% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $46,701,000 | +13.7% | 598,267 | -7.5% | 4.10% | +2.4% |
| INFI | INFINITY PHARMACEUTICALS INC | $41,279,000 | +41.9% | 15,232,268 | 0.0% | 3.63% | +27.7% | |
| KURA | Sell | KURA ONCOLOGY INC | $35,277,000 | -5.8% | 2,015,856 | -2.0% | 3.10% | -15.2% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $34,068,000 | -7.2% | 723,322 | -2.9% | 2.99% | -16.5% |
| ARQL | Sell | ARQULE INC | $32,986,000 | -19.9% | 5,827,902 | -21.8% | 2.90% | -27.9% |
| XNCR | Sell | XENCOR INC | $32,639,000 | +1.4% | 837,538 | -3.7% | 2.87% | -8.7% |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $31,363,000 | +15.7% | 5,600,521 | +4.7% | 2.76% | +4.2% |
| BLRX | BIOLINERX LTDsponsored adr | $27,815,000 | +18.3% | 25,995,575 | 0.0% | 2.44% | +6.4% | |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $26,939,000 | +182.7% | 2,617,967 | +84.6% | 2.37% | +154.5% |
| IONS | Sell | IONIS PHARMACEUTICALS INC | $26,822,000 | +12.9% | 520,000 | -8.8% | 2.36% | +1.7% |
| XOMA | XOMA CORP DEL | $26,404,000 | -15.9% | 1,502,800 | 0.0% | 2.32% | -24.2% | |
| ANAB | Sell | ANAPTYSBIO INC | $24,969,000 | +4.8% | 250,265 | -25.4% | 2.19% | -5.6% |
| GLMD | GALMED PHARMACEUTICALS LTD | $23,922,000 | +14.1% | 1,761,567 | 0.0% | 2.10% | +2.7% | |
| CNCE | Sell | CONCERT PHARMACEUTICALS INC | $23,627,000 | -22.7% | 1,592,138 | -12.4% | 2.08% | -30.5% |
| FWP | Sell | FORWARD PHARMA A/Ssponsored adr | $19,387,000 | -16.2% | 8,502,925 | -0.0% | 1.70% | -24.5% |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $17,581,000 | – | 1,152,073 | +100.0% | 1.54% | – |
| CRVS | CORVUS PHARMACEUTICALS INC | $16,221,000 | -21.9% | 1,890,507 | 0.0% | 1.42% | -29.7% | |
| ACIU | New | AC IMMUNE SA | $16,140,000 | – | 2,017,500 | +100.0% | 1.42% | – |
| IMDZ | Buy | IMMUNE DESIGN CORP | $16,071,000 | -15.1% | 4,658,353 | +12.0% | 1.41% | -23.6% |
| SPRO | Buy | SPERO THERAPEUTICS INC | $15,640,000 | +1.6% | 1,488,088 | +41.9% | 1.37% | -8.5% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $15,385,000 | +132.0% | 1,165,553 | +61.7% | 1.35% | +109.0% |
| MTEM | Buy | MOLECULAR TEMPLATES INC | $15,025,000 | +317.1% | 2,787,629 | +304.8% | 1.32% | +275.0% |
| CTIC | CTI BIOPHARMA CORP | $14,968,000 | -56.6% | 6,929,690 | 0.0% | 1.32% | -61.0% | |
| RCUS | Buy | ARCUS BIOSCIENCES INC | $14,760,000 | +25.6% | 1,058,840 | +10.3% | 1.30% | +13.1% |
| REPL | New | REPLIMUNE GROUP INC | $14,681,000 | – | 911,852 | +100.0% | 1.29% | – |
| VSTM | Sell | VERASTEM INC | $14,406,000 | -6.6% | 1,986,994 | -11.4% | 1.27% | -15.9% |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $13,465,000 | – | 609,014 | +100.0% | 1.18% | – |
| CALA | New | CALITHERA BIOSCIENCES INC | $13,356,000 | – | 2,544,000 | +100.0% | 1.17% | – |
| MEIP | MEI PHARMA INC | $13,276,000 | +9.4% | 3,080,308 | 0.0% | 1.17% | -1.4% | |
| SBPH | Buy | SPRING BK PHARMACEUTICALS INC | $11,487,000 | +23.3% | 953,301 | +21.3% | 1.01% | +11.0% |
| SNDX | SYNDAX PHARMACEUTICALS INC | $9,968,000 | +15.1% | 1,233,618 | 0.0% | 0.88% | +3.7% | |
| OMED | Sell | ONCOMED PHARMACEUTICALS INC | $8,571,000 | -9.5% | 4,042,989 | -1.4% | 0.75% | -18.5% |
| CDTX | CIDARA THERAPEUTICS INC | $8,495,000 | -15.4% | 1,930,670 | 0.0% | 0.75% | -23.9% | |
| VBIV | VBI VACCINES INC | $7,502,000 | -12.0% | 3,100,000 | 0.0% | 0.66% | -20.8% | |
| ALBO | Sell | ALBIREO PHARMA INC | $7,212,000 | -7.7% | 218,800 | -0.5% | 0.63% | -16.8% |
| CFRX | Buy | CONTRAFECT CORP | $7,200,000 | -3.1% | 3,478,326 | +3.5% | 0.63% | -12.7% |
| PRNB | New | PRINCIPIA BIOPHARMA INC | $7,013,000 | – | 240,000 | +100.0% | 0.62% | – |
| MACK | MERRIMACK PHARMACEUTICALS INC | $5,919,000 | +8.5% | 1,110,588 | 0.0% | 0.52% | -2.3% | |
| ARGX | New | ARGENX SEsponsored adr | $5,825,000 | – | 76,808 | +100.0% | 0.51% | – |
| TSRO | New | TESARO INC | $5,461,000 | – | 140,000 | +100.0% | 0.48% | – |
| ERYP | ERYTECH PHARMAsponsored adr | $5,450,000 | -24.4% | 625,000 | 0.0% | 0.48% | -32.0% | |
| GNCA | GENOCEA BIOSCIENCES INC | $4,105,000 | -8.9% | 5,265,000 | 0.0% | 0.36% | -18.0% | |
| ALPN | ALPINE IMMUNE SCIENCES INC | $4,071,000 | -16.4% | 643,059 | 0.0% | 0.36% | -24.6% | |
| SURF | Buy | SURFACE ONCOLOGY INC | $3,941,000 | -27.7% | 360,218 | +7.7% | 0.35% | -35.0% |
| SNSS | SUNESIS PHARMACEUTICALS INC | $3,369,000 | -5.7% | 1,684,636 | 0.0% | 0.30% | -15.2% | |
| RGLS | REGULUS THERAPEUTICS INC | $2,704,000 | -70.0% | 13,685,204 | 0.0% | 0.24% | -73.0% | |
| ADRO | Sell | ADURO BIOTECH INC | $2,115,000 | +2.1% | 287,776 | -2.8% | 0.19% | -7.9% |
| VICL | VICAL INC | $1,826,000 | +19.2% | 1,332,605 | 0.0% | 0.16% | +6.7% | |
| EPIX | Buy | ESSA PHARMA INC | $1,731,000 | -17.2% | 576,771 | +4.3% | 0.15% | -25.5% |
| RLM | New | REALM THERAPEUTICS PLCsponsored ads | $1,173,000 | – | 360,866 | +100.0% | 0.10% | – |
| LOXO | LOXO ONCOLOGY INC | $699,000 | -1.4% | 4,089 | 0.0% | 0.06% | -11.6% | |
| ZYME | ZYMEWORKS INC | $311,000 | +6.1% | 19,804 | 0.0% | 0.03% | -6.9% | |
| TOCA | Exit | TOCAGEN INC | $0 | – | -471,007 | -100.0% | -0.43% | – |
| GTXI | Exit | GTX INC DEL | $0 | – | -386,134 | -100.0% | -0.58% | – |
| IRWD | Exit | IRONWOOD PHARMACEUTICALS INC | $0 | – | -606,715 | -100.0% | -1.13% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
| 3 | 2023-11-06 |
| 4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.